loader2
Partner With Us NRI

Company details

829.00
875.90
478.00
1,198.80
6M Return -5.96%
1Y Return 82.03%
Mkt Cap.(Cr) 805.00
Volume 42
Div Yield 0.49%
OI
-
OI Chg %
-
Volume 42

Open Free Demat Account Online with ICICIDIRECT

SWOT

  • swot

  • technicals

  • deals

  • shareholding


EMA SMA

Delivery and volume

Financials

  • Profit and loss statement

  • Balance sheet

  • Quarterly Result

  • Ratio

Sales(Cr.)

Operating Profit(Cr.)

Profit after Tax(Cr.)

Equity

Reserves and Surplus

Debt

Sales

Operating Profit

Profit after tax

PE

Debt/Equity

P BV

INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 218.51 Cr FV: 10.00
Period MF Net Purchase / (sold) FII Net
LAST 1M 28,019.57 -43,282.61
LAST 3M 77,901.94 -49,701.23
LAST 6M 142,324.16 -198,923.20
LAST 12M 202,461.29 -168,761.49

Information

  • About Company
  • Company Info
  • Listing Info
11.34
67.18%
250.7134
20.82%
21.51%
Description
  • Incorporated in 1969, Themis Medicare Ltd., formerly known as Themis Chemicals (TCL) was originally promoted by Chemosyn and Medimpex but was taken over by a group consisting of Shantibhai D Patel and K T Lakdawala who also have interests in Andhra Synthetics and Antibiotics, which was merged with Artemis Pharmaceuticals in April 93. In Mar.`95, the company came out with a public issue equity shares (premium : Rs 110) to finance the expansion-cum-modernisation of its synthetic bulk drug plant at Vapi, the setting up of a formulation unit at Lilora, Baroda as backward integration and to augment long-term working capital. Total cost of the project was estimated at Rs 17.64 cr. TCL manufactures and sells synthetic bulk drugs and formulations. It operates in the therapeutic segments of anti-tuberculosis, cerebroactivators, bronchodilators, anti-asthmatic, anaesthetic and other segments. Anti-tuberculosis bulk drugs and formulations account for 60% of its turnover and the company is rated fourth in terms of turnover in this segment. TCL has also started manufacturing and exporting fumagillin, an anti-bacterial drug, for veterinary use for which it has a confirmed buy-back arrangement with Chinoin, Hungary. The company with the help of M/s Pharmograd,Moscow a manufacturing unit, is planning to market its Anti-T.B.formulation products through the collborators throughout the Russian Federation for trade,tenders and govt.supplies.

Read More

No Data Found

AGM Date (Month) : Sep
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 530199
NSE Code : THEMISMED
Book Closure Date (Month) : Sep
BSE Group : B
ISIN : INE083B01016

ICICIdirect Themis Medicare Ltd FAQ

You can buy Themis Medicare Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Themis Medicare Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of May 18, 2022 04:01 PM the closing price of Themis Medicare Ltd was ₹ 875.00.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of May 18, 2022 04:01 PM, the market cap of Themis Medicare Ltd stood at ₹ 805.00.
The latest PE ratio of Themis Medicare Ltd as of May 18, 2022 04:01 PM is 11.34
The latest PB ratio of Themis Medicare Ltd as of May 18, 2022 04:01 PM is 0.29
The 52-week high of Themis Medicare Ltd is ₹ 1,198.80 while the 52-week low is ₹ 478.00 .

Thank you for subscribing to Equity/ Equity Research/MF/FnO Newsletter. You will hear from us shortly.

for your vote

CLOSE